Clinical Trial Update: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating stereotactic body radiotherapy with or without pembrolizumab for local-regionally recurrent or second primary head and ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: RTOG Foundation, Inc. | Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING